FDA Drug Regulatory Intelligence

What this FDA regulatory intelligence site tracks

FDA Drug Regulatory Intelligence is an independent index of the public record produced by the United States Food and Drug Administration (FDA), the federal agency that regulates human drugs marketed in the United States. It brings together several streams of administrative information that the FDA already publishes but that are scattered across different systems and file formats: drug recalls recorded in the agency's enforcement reports, drug shortages tracked in the FDA's public shortage database, drug approvals drawn from Drugs@FDA and the Orange Book where a dependable source is available, and a derived manufacturer-level view that rolls those records up by firm name where the source data permits. The goal is narrow and practical: make material that is technically public but hard to navigate easier to find, date and cross-reference.

Each entry on the site is an index pointer back to an official FDA or openFDA record. We do not republish primary documents in full, and we do not add commentary about products or companies beyond the structured, deterministic descriptions generated from the fields the source actually contains. Everything here is regulatory and administrative in nature. There is no clinical interpretation anywhere on the site, and there is nothing here that should be read as guidance about whether to use, avoid, or switch any medicine.

FDA drug recalls

A drug recall is a regulatory action in which a firm removes or corrects a marketed product, working with the FDA, and the agency records the action in its enforcement reports. Recalls are a routine and important part of pharmaceutical oversight: they are the mechanism by which a problem identified after a product reaches the market is formally addressed. The FDA assigns each recall a classification — Class I, Class II or Class III — that describes the agency's regulatory assessment of the recall event. On this site those classifications are presented strictly as the agency's administrative severity tiers, never as a personalised risk statement for any individual.

Our recalls section indexes the most recent enforcement reports from the openFDA Drug Enforcement API, normalises the firm names, dates and classification fields, and presents each report on a stable URL with a link straight back to the verifiable source. You can browse the most recent recalls, filter by classification, and follow a record through to the official FDA entry. The indexed dataset currently records 9 Class I, 219 Class II and 22 Class III recall entries. Visit the drug recalls hub for the full explanation and the latest records.

FDA drug shortages

A drug shortage is a period during which the supply of a drug product does not meet demand at the patient or provider level, as tracked by the FDA. The agency maintains a public database of current and resolved shortages, recording the affected product, the reporting company, the status of the shortage, and supporting availability information. Shortages matter to hospital pharmacies, group purchasing organisations, manufacturers and distributors because they drive procurement planning and supply-chain risk management.

Our shortages section indexes the FDA's public shortage data, normalises the product names, companies, statuses and dates, and presents each entry on a stable URL alongside a link to the official source. The indexed dataset currently records 238 current and 0 resolved shortage entries. Importantly, this site never suggests therapeutic substitutions or alternatives; it reports the regulatory supply signal and points you to the official record. See the drug shortages hub for the latest entries and a full explanation of how the data is structured.

FDA approvals and product data

The FDA's approval records — held in Drugs@FDA and the Orange Book data files — describe which products have been authorised for marketing, their application numbers, sponsors, product forms and marketing status. This layer is the most demanding to ingest reliably without a browser or bulk-file pipeline, so on this site it is treated conservatively. Where a dependable, machine-readable source is available, approval records are indexed and cross-linked to the relevant manufacturer; where it is not, the approvals layer is explicitly marked as deferred rather than promising data the site does not have. The approvals layer currently has indexed records. You can read exactly what is and is not available on the drug approvals page.

Manufacturer-level regulatory signals

Beyond individual records, this site derives a manufacturer-level view that aggregates how often a firm appears across the indexed recall and shortage datasets. For each firm we show a recall count, a shortage count, the date and type of the most recent record, and links to the underlying entries. These counts are coverage-limited activity signals: they reflect how frequently a firm shows up in these particular public records over the ingested window. They are not quality ratings, reputational scores, or judgements about a company or its products, and they should never be read that way. Recalls and shortages are normal features of pharmaceutical regulation, and their presence in these datasets is an administrative fact, not an indication of danger or wrongdoing.

Counts are not quality ratings. They are coverage-limited activity signals showing how often a firm appears in the indexed FDA records — not judgements about the firm or its products.

All manufacturer regulatory signals →

What this site does not provide

This site provides no medical advice of any kind. There is no diagnosis, no dosage information, no discussion of side effects, no treatment or therapeutic recommendation, and no statement that any product is safe or unsafe for a particular person. It does not tell you to start, stop, switch or avoid any medicine, and it does not suggest substitutes for products in shortage. It does not rank or rate manufacturers, and the counts shown on manufacturer pages are coverage-limited activity signals, never quality scores. It is not an official government service, and it cannot answer questions about your personal health. For anything clinical, consult a qualified healthcare professional; for anything authoritative, consult the FDA directly through the official links provided on every page.

Latest FDA records

All recalls → · All shortages →

Methodology and source limitations

The data is ingested from the FDA's public surfaces — primarily the openFDA Drug Enforcement and Drug Shortages APIs, with Drugs@FDA and Orange Book data considered for the approvals layer — then normalised into consistent records, hashed for change detection, and rebuilt into static pages. We deliberately index the machine-readable layer and do not scrape behind logins or captchas. Coverage is therefore partial by construction: each dataset exposes only certain fields, the approvals layer may be deferred, and ingestion reflects a point in time that can lag the live record. We never invent a product name, firm or date that the source does not state. The full approach — sources, ingestion, normalisation, record hashing, freshness and the data-correction policy — is documented on the methodology page, the individual data sources are listed here, and key terms are defined in the regulatory intelligence glossary.